VEGFR2-IN-86
VEGFR2-IN-86 is a dual VEGFR2/CDK2 inhibitor, with an IC50 of 0.06 μM against VEGFR2 and an IC50 of 0.78 μM against CDK2. VEGFR2-IN-86 induces G-phase cell cycle arrest, reduces colony-forming ability and tumor cell migration capacity, and exerts antiproliferative activity in cancer cells. VEGFR2-IN-86 can be used for the research of breast cancer and prostate cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C20H15N3O2
- Molecular Weight:329.35
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle VEGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
VEGFR2 0.06 μM (IC50) |
CDK2 0.78 μM (IC50) |
VEGFR2-IN-86 (Compound 10) (48 h) potently inhibits the viability of PC3 and MCF7 cells, with IC50 values of 5.39 and 4.71 μM[1].
VEGFR2-IN-86 (5.39 and 4.71 μM; 48 h) induces apoptosis in PC3 and MCF7 cells after treatment at its IC50 concentration for 48 hours[1].
VEGFR2-IN-86 (5.39 and 4.71 μM; 48 h) does not significantly alter the cell cycle phase distribution of PC3 and MCF7 cells[1].
VEGFR2-IN-86 (5.39 and 4.71 μM; 48 h) potently inhibits the long-term clonogenic survival of PC3 and MCF7 cells when acting at IC50 concentrations for 48 hours[1].
VEGFR2-IN-86 (5.39 and 4.71 μM; 48 h) inhibits the migration of PC3 and MCF7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC3 prostate cancer cell line
-
Concentration:5.39 μM (IC50)
-
Incubation Time:48 h
-
Result:Resulted in a cell cycle phase distribution pattern comparable to untreated control cells, with no significant alteration in G1, S, or G2/M phase populations relative to control.
-
Cell Line:MCF7 breast cancer cell line
-
Concentration:4.71 μM (IC50)
-
Incubation Time:48 h
-
Result:Produced no significant alterations in G1, S, or G2/M phase populations relative to untreated control cells.
-
Cell Line:PC3 prostate cancer cell line
-
Concentration:5.39 μM (IC50)
-
Incubation Time:48 h (treatment); 14 days (colony formation)
-
Result:Markedly suppressed colony formation, resulting in a surviving fraction significantly lower than that of untreated control cells.
-
Cell Line:MCF7 breast cancer cell line
-
Concentration:4.71 μM (IC50)
-
Incubation Time:48 h (treatment); 14 days (colony formation)
-
Result:Markedly suppressed colony formation, resulting in a surviving fraction significantly lower than that of untreated control cells.
-
Cell Line:PC3 prostate cancer cell line
-
Concentration:5.39 μM (IC50)
-
Incubation Time:48 h
-
Result:Resulted in a scratch closure percentage of 73%, showing a slight reduction compared to the untreated control's 78% closure.
-
Cell Line:MCF7 breast cancer cell line
-
Concentration:4.71 μM (IC50)
-
Incubation Time:48 h
-
Result:Resulted in a scratch closure percentage of 26%, showing a marked reduction compared to the untreated control's 64% closure.
Chemical Information
-
Molecular Weight 329.35
-
Formel C20H15N3O2
-
SMILES
O=C1NC2=C(C=CC=C2)/C1=C\C(C3=C(C)N=C(C4=CC=CC=C4)N3)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
VEGFR2-IN-86 Related Classifications
HY-182789 Related Classifications
Powered by Bioz